Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Fishbane

Showing results (171-180 of 234) with videos related to

Pageof 24
Sort By:
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 4, 2014
A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5Geoffrey A Block, Steven Fishbane, Mariano Rodriguez, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|September 30, 2005
The effect of a change in epoetin alfa reimbursement policy on anemia outcomes in hemodialysis patientsJeffrey S Berns, Steven Fishbane, Hafez Elzein, et al.
Kidney International Reports|May 5, 2018
Potentially Avoidable Readmissions in United States Hemodialysis PatientsAnna T Mathew, Lisa Rosen, Renee Pekmezaris, et al.
Seminars in Dialysis|January 21, 2006
How should chronic medical therapies be altered with the onset of end-stage renal disease and initiation of dialysis?Kathleen L Wyne, Steven Fishbane, Geoffrey A Block, et al.
American Journal of Hematology|March 26, 2018
Hemoglobin response to ferric citrate in patients with nondialysis-dependent chronic kidney disease and iron deficiency anemiaPablo E Pergola, Steven Fishbane, Robin D LeWinter, et al.
Journal of the American Society of Nephrology : JASN|December 28, 2014
Considerations and challenges in defining optimal iron utilization in hemodialysisDavid M Charytan, Amy Barton Pai, Christopher T Chan, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 1, 2010
A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysisSteven Fishbane, James Delmez, Wadi N Suki, et al.
Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation|August 8, 2021
Consensus-Based Recommendations for the Management of Hyperkalemia in the Hemodialysis SettingSteven Fishbane, David M Charytan, Glenn M Chertow, et al.
American Journal of Nephrology|January 22, 2024
Difelikefalin in Black/African American Hemodialysis Patients with Moderate-to-Severe Pruritus: Post hoc Analysis of KALM-1 and KALM-2Steven Fishbane, Deborah J Clegg, Edgar V Lerma, et al.
Kidney Medicine|August 1, 2020
Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label StudiesJay B Wish, Marcelo G Rocha, Nancy E Martin, et al.
Pageof 24

Showing results (171-180 of 234) with videos related to

Sort By:
Pageof 24
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 4, 2014
A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5Geoffrey A Block, Steven Fishbane, Mariano Rodriguez, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|September 30, 2005
The effect of a change in epoetin alfa reimbursement policy on anemia outcomes in hemodialysis patientsJeffrey S Berns, Steven Fishbane, Hafez Elzein, et al.
Kidney International Reports|May 5, 2018
Potentially Avoidable Readmissions in United States Hemodialysis PatientsAnna T Mathew, Lisa Rosen, Renee Pekmezaris, et al.
Seminars in Dialysis|January 21, 2006
How should chronic medical therapies be altered with the onset of end-stage renal disease and initiation of dialysis?Kathleen L Wyne, Steven Fishbane, Geoffrey A Block, et al.
American Journal of Hematology|March 26, 2018
Hemoglobin response to ferric citrate in patients with nondialysis-dependent chronic kidney disease and iron deficiency anemiaPablo E Pergola, Steven Fishbane, Robin D LeWinter, et al.
Journal of the American Society of Nephrology : JASN|December 28, 2014
Considerations and challenges in defining optimal iron utilization in hemodialysisDavid M Charytan, Amy Barton Pai, Christopher T Chan, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 1, 2010
A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysisSteven Fishbane, James Delmez, Wadi N Suki, et al.
Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation|August 8, 2021
Consensus-Based Recommendations for the Management of Hyperkalemia in the Hemodialysis SettingSteven Fishbane, David M Charytan, Glenn M Chertow, et al.
American Journal of Nephrology|January 22, 2024
Difelikefalin in Black/African American Hemodialysis Patients with Moderate-to-Severe Pruritus: Post hoc Analysis of KALM-1 and KALM-2Steven Fishbane, Deborah J Clegg, Edgar V Lerma, et al.
Kidney Medicine|August 1, 2020
Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label StudiesJay B Wish, Marcelo G Rocha, Nancy E Martin, et al.
Pageof 24